Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisCharles V. Pollack, Jeffrey I. Weitz, Jörg Kreuzer et al.|New England Journal of Medicine|2017Cited by 1.1k
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranPaul A. Reilly, Charles V. Pollack, Richard A. Bernstein et al.|Thrombosis and Haemostasis|2015Cited by 154
Distribution of a novel cardioactive neuropeptide (CCAP) in the nervous system of the shore crab Carcinus maenasJoachim Stangier, Rainer Keller, C. Hilbich et al.|Peptides|1988Cited by 68
Identification and immunocytochemical localization of proctolin in pericardial organs of the shore crab, Carcinus maenasJoachim Stangier, Rainer Keller, Heinrich Dircksen|Peptides|1986Cited by 60
INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONSCharles V. Pollack, CW Kam, John W. Eikelboom et al.|Emergency Medicine Journal|2015Cited by 7